A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Nuclear Medicine"
DOI: 10.2967/jnumed.121.261936
Abstract: Visual Abstract 68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high sensitivity and reproducibility in neuroendocrine tumor (NET) detection and localization. However, the optimal peptide mass and radioactivity ranges for 68Ga-satoreotide trizoxetan have… read more here.
Keywords: 68ga satoreotide; peptide mass; radioactivity; satoreotide trizoxetan ... See more keywords